Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the
growth of cancer cells. It also helps stop the patient's immune system from rejecting the
transplanted stem cells. When the healthy stem cells are infused into the patient they may
help the patient's bone marrow make stem cells, red blood cells, white blood cells, and
platelets. If the patient's stem cells are to be transplanted, the patient is also treated
with a monoclonal antibody, such as gemtuzumab ozogamicin, to kill any remaining cancer cells
or deliver cancer-killing substances to them without harming normal cells. It is not yet
known whether combination chemotherapy is more effective with or without gemtuzumab
ozogamicin followed by stem cell transplant in treating acute myeloid leukemia.
PURPOSE: This randomized phase III trial is studying combination chemotherapy, gemtuzumab
ozogamicin, and stem cell transplant to see how well they work compared to combination
chemotherapy and peripheral stem cell transplant alone in treating patients with acute
myeloid leukemia.